News | Radiology Imaging | January 22, 2020

Groups Publish Statements on CT Contrast Use in Patients with Kidney Disease

Iodine-based CT contrast ready for scanning with a Canon Aquilion One 320-slice CT system at Northwestern Medicine Central DuPage Hospital in the Chicago suburbs.

January 22, 2020 — The risk of administering modern intravenous iodinated contrast media in patients with reduced kidney function has been overstated, according to new consensus statements from the American College of Radiology (ACR) and the National Kidney Foundation (NKF), published in the journal Radiology.

Intravenous iodinated contrast media are commonly used with computed tomography (CT) to evaluate disease and to determine treatment response. Although patients have benefited from their use, iodinated contrast media have been denied or delayed in patients with reduced kidney function due to the perceived risks of contrast-induced acute kidney injury. This practice can hinder a timely and accurate diagnosis in these patients.

"The historical fears of kidney injury from contrast-enhanced CT have led to unmeasured harms related to diagnostic error and diagnostic delay," said lead author Matthew S. Davenport, M.D., associate professor of radiology and urology at the University of Michigan in Ann Arbor, Mich. "Modern data clarify that this perceived risk has been overstated. Our intent is to provide multi-disciplinary guidance regarding the true risk to patients and how to apply a consideration of that risk to modern clinical practice."

These consensus statements were developed to improve and standardize the care of patients with impaired kidney function who may need to undergo exams that require intravenous iodinated contrast media to provide the clearest images and allow for the most informed diagnosis.

In clinical practice, many factors are used to determine whether intravenous contrast media should be administered. These include probability of an accurate diagnosis, alternative methods of diagnosis, risks of misdiagnosis, expectations about kidney function recovery, and risk of allergic reaction. Decisions are rarely based on a single consideration, such as risk of an adverse event specifically related to kidney impairment. Consequently, the authors advise that these statements be considered in the context of the entire clinical scenario.

Importantly, the report outlines the key differences between contrast-induced acute kidney injury (CI-AKI) and contrast-associated acute kidney injury (CA-AKI). In CI-AKI, a causal relationship exists between contrast media and kidney injury, whereas in CA-AKI, a direct causal relationship has not been demonstrated. The authors suggest that studies that have not properly distinguished the two have contributed to the overstatement of risk.

"A primary explanation for the exaggerated perceived nephrotoxic risk of contrast-enhanced CT is nomenclature," Davenport said. "'Contrast-induced' acute kidney injury implies a causal relationship. However, in many circumstances, the diagnosis of CI-AKI in clinical care and in research is made in a way that prevents causal attribution. Disentangling contrast-induced AKI (causal AKI) from contrast-associated AKI (correlated AKI) is a critical step forward in improving understanding of the true risk to patients."

The statements answer key questions and provide recommendations for use of intravenous contrast media in treating patients with varying degrees of impaired kidney function.

Although the true risk of CI-AKI remains unknown, the authors recommend intravenous normal saline for patients without contraindication, such as heart failure, who have acute kidney injury or an estimated glomerular filtration rate (eGFR) less than 30 mL/min per 1.73 m2 who are not undergoing maintenance dialysis. In individual and unusual high-risk circumstances (patients with multiple comorbid risk factors), prophylaxis may be considered in patients with an eGFR of 30-44 mL/min per 1.73 m2 at the discretion of the ordering clinician.

The presence of a solitary kidney should not independently influence decision making regarding the risk of CI-AKI. Lowering of contrast media dose below a known diagnostic threshold should be avoided due to the risk of lowering diagnostic accuracy. Also, when feasible, medications that are toxic to the kidneys should be withheld by the referring clinician in patients at high risk. However, renal replacement therapy should not be initiated or altered solely based on contrast media administration.

The authors emphasize that prospective controlled data are needed in adult and pediatric populations to clarify the risk of CI-AKI.

For more information: www.rsna.org

Related Content of MRI Gadolinium Safety Concerns

Voluntary Dismissal of Chuck Norris Gadolinium Case Involving Bracco

VIDEO: How Serious is MRI Gadolinium Retention in the Brain and Body? An interview with Max Wintermark, M.D.

VIDEO “Big Concerns Remain for MRI Gadolinium Contrast Safety at RSNA 2017,” An interview with Emanuel Kanal, M.D.

Radiology Has Failed to Properly Assess or Track MRI Gadolinium Contrast Safety

Recent Developments in Contrast Media

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents

European Medicines Agency Issues Update on Gadolinium Contrast Agents

 

Related Content

Emagine Solutions Technology's VistaScan portable ultrasound enables doctors to enhance patient care. Clinicians can diagnose in moments, saving time and lives at a fraction of the cost of a cart ultrasound machine

Emagine Solutions Technology's VistaScan portable ultrasound enables doctors to enhance patient care. Clinicians can diagnose in moments, saving time and lives at a fraction of the cost of a cart ultrasound machine. Photo credit: Tech Parks Arizona

News | Ultrasound Imaging | February 27, 2020
February 27, 2020 — Emagine Solutions Technology, an award-winnin
In a study of more than 1,000 patients published in the journal Radiology, chest CT outperformed lab testing in the diagnosis of 2019 novel coronavirus disease (COVID-19) #COVID19 #COVID-2019 #2019nCoV

Chest CT images of a 29-year-old man with fever for 6 days. RT-PCR assay for the SARS-CoV-2 using a swab sample was performed on Feb. 5, 2020, with a positive result. (A column) Normal chest CT with axial and coronal planes was obtained at the onset. (B column) Chest CT with axial and coronal planes shows minimal ground-glass opacities in the bilateral lower lung lobes (yellow arrows). (C column) Chest CT with axial and coronal planes shows increased ground-glass opacities (yellow arrowheads). (D column) Chest CT with axial and coronal planes shows the progression of pneumonia with mixed ground-glass opacities and linear opacities in the subpleural area. (E column) Chest CT with axial and coronal planes shows the absorption of both ground-glass opacities and organizing pneumonia. Image courtesy of Radiology

News | Computed Tomography (CT) | February 26, 2020 | Melinda Taschetta-Millane and Dave Fornell
February 26, 2020 — In a study of m
 over the course of a week and a half #coronavirus #COVID19 #COVID-2019 #2019nCoV

29-year old male with unknown exposure history, presenting with fever and cough, ultimately requiring intensive care unit admission. (a) Axial thin-section non-contrast CT scan shows diffuse bilateral confluent and patchy ground-glass (solid arrows) and consolidative (dashed arrows) pulmonary opacities. (b) The disease in the right middle and lower lobes has a striking peripheral distribution (arrow). Image courtesy of Radiology 

News | Computed Tomography (CT) | February 26, 2020
February 26, 2020 — Mount Sinai Health System physicians—the
Images in a 41-year-old woman who presented with fever and positive polymerase chain reaction assay for the 2019 novel coronavirus (2019-nCoV) #coronavirus #nCoV2019 #2019nCoV #COVID19

Images in a 41-year-old woman who presented with fever and positive polymerase chain reaction assay for the 2019 novel coronavirus (2019-nCoV). Three representative axial thin-section chest CT images show multifocal ground glass opacities without consolidation. Three-dimensional volume-rendered reconstruction shows the distribution of the ground-glass opacities (arrows). Image courtesy of the Radiological Society of North America (RSNA)

News | Radiology Imaging | February 25, 2020
February 24, 2020 — The U.S.
Carestream’s state-of-the-art OnSight 3D Extremity System
News | Computed Tomography (CT) | February 25, 2020
February 25, 2020 — Carestream’s state-of-the-art...
An axial CT image obtained without intravenous contrast in a 36‐year‐old male (Panel A) shows bilateral ground‐glass opacities in the upper lobes with a rounded morphology (arrows). #coronavirus #nCoV2019 #2019nCoV #COVID19

An axial CT image obtained without intravenous contrast in a 36‐year‐old male (Panel A) shows bilateral ground‐glass opacities in the upper lobes with a rounded morphology (arrows). Image courtesy of Radiology Online.

News | Computed Tomography (CT) | February 20, 2020
February 20, 2020 — In new research